SDV-HGNN: similarity-based dual view heterogeneous graph neural network method for drug adverse side effect prediction
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background: Drug adverse side effects (ASEs) significantly impact public health, healthcare costs, and drug discovery processes. As medication usage increases, effective management of drug side effects becomes crucial. Previ- ous research has focused on single-perspective drug features such as chemical structure or topological information from knowledge graphs. Recent approaches attempt to learn separately from molecular graphs and drug-side effect net- works, combining these representations for prediction. However, these methods often report limited performance metrics and may not fully capture the complex interplay between molecular structures and broader drug-side effect relationships. Results : We propose a novel Similarity-based Dual View Heterogeneous Graph Neural Network (SDV-HGNN) for predicting drug adverse side effects. This approach simultaneously learns microscopic drug substructure features from the molecular graph and macroscopic features from a connectivity-enhanced Drug- adverse Side-effect Network (DSN). We introduced four additional edges between drugs and three between side effects using multiple context-specific similarity metrics. The problem is framed as a binary classification task within the context of link prediction on a graph. Our model demonstrated superior performance in 10-fold cross-validation (CV) using a benchmark dataset, achieving an AUROC of 0.8989 ± 0.0069, AUPR 0.9093 ± 0.0068, and F1 0.8261 ± 0.0056. The source code is available from GitHub at https://github.com/mayankkom-dev/ SDV-HGNN. Conclusions : The SDV-HGNN model shows promising results in predicting drug adverse side effects by leveraging both microscopic and macroscopic features simultaneously. By reporting a comprehensive set of performance metrics, our study provides a more thorough evaluation of the model’s capabilities, addressing previous research limitations.